Infection patterns in newly diagnosed AML patients
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at infections in people with newly diagnosed acute myeloid leukemia (AML) starting from March 2025. It aims to understand how often infections happen and how they affect patients, so doctors can improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have been newly diagnosed with acute myeloid leukemia (AML), including a subtype called APL, on or after March 1, 2025.
- You are either not receiving any chemotherapy (only supportive care), or you are getting induction or consolidation therapy, or your AML has come back or did not respond to treatment (with first diagnosis after March 1, 2025).
- You have had an infection (diagnosed by symptoms or lab tests) or a fever with unknown cause since your AML diagnosis.
- You do not have other blood cancers besides AML.
- You have not had a stem cell transplant (from yourself or a donor) for AML.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how inflammation (the body's response to injury or infection) affects treatment outcomes in people with acute myeloid leukemia (AML). If you have a new diagnosis or have stored samples from a past diagnosis, you may help researchers understand why some people respond better to therapy.
This study looks at how often a serious bowel problem (neutropenic enterocolitis) happens in adults with acute myeloid leukemia (AML) during intensive chemotherapy that lowers infection-fighting cells. The results may help doctors monitor and prevent complications during treatment.
This registry collects information from adults with AML diagnosed since 2020. It helps doctors understand and improve treatment for this blood cancer.
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
This study looks at how acute myeloid leukemia behaves over time in adults and may help doctors better predict outcomes. You might be eligible if you have AML and agree to take part in research.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.